½ÃÀ庸°í¼­
»óǰÄÚµå
1602723

¼¼°èÀÇ ÁøÅëÁ¦ ½ÃÀå : ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Analgesics Market by Drug Type (Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, Salicylates), Type (Non-Opioids, Opioids), Route of Administration, Distribution - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÁøÅëÁ¦(Analgesics) ½ÃÀåÀº 2023³â¿¡ 218¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 237¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤ µÇ¸ç, CAGR 8.79%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 394¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁøÅëÁ¦ ½ÃÀåÀº ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ, À̺ÎÇÁ·ÎÆæ°ú °°Àº ÀϹÝÀǾàǰºÎÅÍ Ã³¹æ¿ë ¿ÀÇÇ¿ÀÀÌµå ¹× °í±Þ Á¦Çü¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÁøÅëÁ¦¸¦ ¾Æ¿ì¸¨´Ï´Ù. ÁøÅëÁ¦´Â ¸¸¼º Áúȯ, ¼ö¼ú ÈÄ È¸º¹, ±Þ¼º ºÎ»ó µî ´Ù¾çÇÑ ÁúȯÀ¸·Î ÀÎÇÑ ÅëÁõÀ» ¿ÏÈ­Çϱâ À§ÇØ ÀÇ·á ºÐ¾ß¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù. ÁøÅëÁ¦´Â º´¿ø, Ŭ¸®´Ð, ¼Ò¸Å ¾à±¹, ȨÄÉ¾î µî ´Ù¾çÇÑ È¯°æ¿¡¼­ »ç¿ëµÇ¸ç, °³ÀÎ ¼ÒºñÀÚºÎÅÍ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÃÖÁ¾ »ç¿ëÀÚ¿¡°Ô ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÁøÅëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ÀÇ Áõ°¡, ºñħ½ÀÀû ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀǾàǰ °³¹ß, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü, ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í °°Àº »õ·Î¿î Æ®·»µå´Â »ó´çÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ±ÔÁ¦ Á¶»ç, ¿ÀÇÇ¿ÀÀ̵å¿Í °ü·ÃµÈ Áßµ¶ À§Çè, Á¦³×¸¯ ÀǾàǰÀÇ ½ÃÀå Æ÷È­ µîÀÇ µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±â¾÷Àº ¾à¹° Á¦Çü Çõ½Å¿¡ ÁýÁßÇÏ°í ½Ã³ÊÁö È¿°ú¸¦ ³¾ ¼ö ÀÖ´Â ÆÄÆ®³Ê½ÊÀ» ¸ð»öÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù. õ¿¬ ¹× ½Ä¹°¼º ÁøÅëÁ¦¿¡ ´ëÇÑ R&D ÅõÀÚ¸¦ ´Ã¸®¸é °Ç°­¿¡ °ü½ÉÀÌ ¸¹Àº ¼ÒºñÀڵ鿡°Ô Â÷º°È­µÇ°í ¾îÇÊÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½º¸¶Æ® ¿þ¾î·¯ºí ¹× ¸ð¹ÙÀÏ ¾Û°ú °°Àº ±â¼úÀ» ±â¹ÝÀ¸·Î ÇÑ ÅëÁõ °ü¸® ¼Ö·ç¼ÇÀ» Ž»öÇϸé ÅëÁõ °ü¸® ÇÁ·ÎÅäÄÝ¿¡ ´ëÇÑ Âü¿©¿Í ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ °æÀïÀû Ư¼ºÀ¸·Î ÀÎÇØ »õ·Î¿î ÁøÅëÁ¦ Á¦Ç°ÀÇ ÀåÁ¡°ú ¾ÈÀü¼ºÀ» °­Á¶ÇÏ´Â Àü·«Àû ¸¶ÄÉÆÃ°ú ¼ÒºñÀÚ ±³À°ÀÇ Á߿伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. Áö¼Ó °¡´ÉÇÑ ¼ºÀåÀ» º¸ÀåÇϱâ À§ÇØ ±â¾÷Àº ¾ÈÀüÇϰí È¿°úÀûÀÎ ºñ¿ÀÇÇ¿ÀÀ̵å Á¦Çü¿¡ ¿ì¼±ÀûÀ¸·Î ÅõÀÚÇϰí ÀÇ·á ¼öÁØÀÌ ³ô¾ÆÁö´Â ½ÅÈï ½ÃÀåÀ¸·Î Áö¸®Àû ÀÔÁö¸¦ È®ÀåÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãø¸éÀ» ÇØ°áÇÔÀ¸·Î½á ±â¾÷Àº »õ·Î¿î ¼öÀÍ¿øÀ» âÃâÇÏ´Â µ¿½Ã¿¡ ±Û·Î¹ú ÇコÄÉ¾î ½ÃÀå¿¡ ±àÁ¤ÀûÀ¸·Î ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 218¾ï 5,000¸¸ ´Þ·¯
ÃßÁ¤¿¬µµ(2024³â) 237¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø¿¬µµ(2030³â) 394¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 8.79%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÁøÅëÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ÀλçÀÌÆ® °ø°³

ÁøÅëÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÉÇ÷°üÁúȯ(CVD), ¾Ï, °üÀý¿°ÀÇ ÀÌȯÀ² »ó½Â
    • Áö¿ª¿¡ °ÅÁÖÇÏ´Â °í·ÉÀÚ¿¡¼­ Á¤±âÀûÀÎ ÁøÅë Ä¡·áÀÇ À¯º´·ü Áõ°¡
    • ½ÃÆÇ ÁøÅëÁ¦ÀÇ ºñ¿ë ´ëºñ È¿°ú
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿ÀÇÇ¿ÀÀ̵åÀÇ ¹«Áú¼­ÇÑ Ã³¹æ°ú ¾à¹° ³²¿ë
  • ½ÃÀå ±âȸ
    • °ü¹Î¿¡ ÀÇÇÑ R&D ÅõÀÚ Áõ°¡
    • ¸ÂÃãÇü ÀÇ·áÀÇ ÀαⰡ Áõ°¡
  • ½ÃÀå °úÁ¦
    • ¿ÀÇÇ¿ÀÀ̵带 Æ÷ÇÔÇÑ È¿´ÉÀÌ ³ôÀº ÀǾàǰ À̿밡´É¼º ¹× °¡°Ý Á¦ÇÑ ÁøÅëÁ¦

Porter's Five Forces : ÁøÅëÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ºñÁî´Ï½º Á¶Á÷ÀÌ °æÀïÀû À§Ä¡¸¦ Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ý·ÐÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÈûÀÇ ¿ªÇÐ °ü°è¸¦ Æò°¡ÇÏ°í »õ·Î¿î º¥Ã³ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϸç ÀáÀçÀûÀÎ ¹®Á¦¸¦ ¹æÁöÇÏ¿© º¸´Ù ź·ÂÀûÀÎ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÁøÅëÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÁøÅëÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡, °æÁ¦, »çȸ, ±â¼ú, ¹ý·ü ¹× ȯ°æ ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ¿© ¼±Á¦ÀûÀÌ°í ¹Ì·¡ ÁöÇâÀûÀÎ ÀÇ»ç °áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ÁøÅëÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÁøÅëÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°úÀÇ Á¾ÇÕÀûÀÎ Æò°¡¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü µîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï ¿ìÀ§¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁßµµ, ¼¼ºÐÈ­, ÅëÇÕ Ãß¼¼¸¦ °­Á¶ÇÏ¿© º¥´õ°¡ °æÀïÀÌ Ä¡¿­ÇØÁö´Â ȯ°æ¿¡¼­ ÀÔÁö¸¦ °­È­ÇÏ´Â Àü·«Àû °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÁøÅëÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÁøÅëÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤È®ÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

Àü·« ºÐ¼® ¹× Á¦¾È : ÁøÅëÁ¦ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸®±â

ÁøÅëÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ½ÉÇ÷°üÁúȯ(CVD), ¾Ï, °üÀý¿° ¹ß»ý·ü »ó½Â
      • Áö¿ª °ÅÁÖÀÇ °í·ÉÀÚ¿¡¼­ Á¤±âÀûÀÎ ÁøÅë Ä¡·áÀÇ º¸±Þ·üÀÌ »ó½Â
      • ½ÃÆÇ ÁøÅëÁ¦ÀÇ ºñ¿ë ´ëºñ È¿°ú
    • ¾ïÁ¦¿äÀÎ
      • ¿ÀÇÇ¿ÀÀ̵åÀÇ ¹«Áú¼­ÇÑ Ã³¹æ°ú ¾à¹° ³²¿ë
    • ±âȸ
      • °ü¹Î¿¡ ÀÇÇÑ R&D ÅõÀÚ Áõ°¡
      • ¸ÂÃãÇü ÀÇ·áÀÇ ÀαⰡ Áõ°¡
    • °úÁ¦
      • ¿ÀÇÇ¿ÀÀ̵带 Æ÷ÇÔÇÑ °íÈ¿´É¾àÀÇ ÀÔ¼ö¼º°ú °¡°ÝÀÌ ÇÑÁ¤µÇ¾î ÀÖ´Â ÁøÅëÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ¹ýÀû
    • ȯ°æÀû

Á¦6Àå ÁøÅëÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°

  • ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦
  • »ì¸®½Ç»ê¿°

Á¦7Àå ÁøÅëÁ¦ ½ÃÀå : À¯Çüº°

  • ºñ¿ÀÇÇ¿ÀÀ̵å
  • ¿ÀÇÇ¿ÀÀ̵å

Á¦8Àå ÁøÅëÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°

  • Á¤¸Æ³»
  • °æ±¸
  • Á÷Àå
  • ±¹¼Ò
  • °æÇÇ

Á¦9Àå ÁøÅëÁ¦ ½ÃÀå : À¯Åë¿øº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÁøÅëÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ ÁøÅëÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁøÅëÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • AbbVie Inc.
  • Assertio Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • Glaxosmithkline PLC
  • Johnson&Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharmaceuticals LP
  • Reckitt Benckiser Group PLC
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceutical Industries Ltd.
LYJ

The Analgesics Market was valued at USD 21.85 billion in 2023, expected to reach USD 23.75 billion in 2024, and is projected to grow at a CAGR of 8.79%, to USD 39.42 billion by 2030.

The analgesics market encompasses a wide range of pain-relieving medications, from over-the-counter options like acetaminophen and ibuprofen to prescription opioids and advanced formulations. Analgesics are essential in healthcare for alleviating pain from various conditions, such as chronic illnesses, post-surgical recovery, and acute injuries. Their application extends across multiple settings, including hospitals, clinics, retail pharmacies, and home care, serving diverse end-users ranging from individual consumers to healthcare providers. Growth in the analgesics market is driven by increased prevalence of chronic diseases, rising geriatric population, and growing demand for non-invasive pain management solutions. Emerging trends such as the development of personalized medicine, advancements in drug delivery systems, and the rising focus on non-opioid analgesics offer significant growth opportunities. However, the market faces challenges from regulatory scrutiny, addiction risks associated with opioids, and market saturation of generic medications. Companies can navigate these challenges by focusing on innovation in drug formulation and exploring synergistic partnerships for broadened reach. Increased funding into R&D for natural and plant-based analgesics presents a viable opportunity for differentiation and appeal to health-conscious consumers. Moreover, exploring pain management solutions powered by technology, like smart wearables and mobile apps, can drive engagement and adherence in pain management protocols. The market's competitive nature emphasizes the importance of strategic marketing and consumer education to highlight the benefits and safety of new analgesic products. To ensure sustainable growth, businesses should prioritize investments in safe, effective non-opioid formulations and expand their geographical footprints to emerging markets with rising healthcare standards. By addressing these aspects, companies can unlock new revenue streams while contributing positively to global healthcare markets.

KEY MARKET STATISTICS
Base Year [2023] USD 21.85 billion
Estimated Year [2024] USD 23.75 billion
Forecast Year [2030] USD 39.42 billion
CAGR (%) 8.79%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Analgesics Market

The Analgesics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of cardiovascular disease (CVD), cancer, & arthritis
    • Prevalence of regular analgesic treatment has increased among community-dwelling older person
    • Cost-effectiveness of over-the-counter analgesic medications
  • Market Restraints
    • Uncontrolled prescriptions of opioids and drug abuse
  • Market Opportunities
    • Increasing investments in R&D by the public & private sectors
    • Surge in popularity of personalized medicine
  • Market Challenges
    • Limited availability and affordability of high efficacy drugs, including opioid analgesics

Porter's Five Forces: A Strategic Tool for Navigating the Analgesics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Analgesics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Analgesics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Analgesics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Analgesics Market

A detailed market share analysis in the Analgesics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Analgesics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Analgesics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Analgesics Market

A strategic analysis of the Analgesics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Analgesics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Assertio Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo Pharmaceuticals Inc., Glaxosmithkline PLC, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Purdue Pharmaceuticals L.P., Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Analgesics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Salicylates.
  • Based on Type, market is studied across Non-Opioids and Opioids.
  • Based on Route of Administration, market is studied across Intravenous, Oral, Rectal, Topical, and Transdermal.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of cardiovascular disease (CVD), cancer, & arthritis
      • 5.1.1.2. Prevalence of regular analgesic treatment has increased among community-dwelling older person
      • 5.1.1.3. Cost-effectiveness of over-the-counter analgesic medications
    • 5.1.2. Restraints
      • 5.1.2.1. Uncontrolled prescriptions of opioids and drug abuse
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D by the public & private sectors
      • 5.1.3.2. Surge in popularity of personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability and affordability of high efficacy drugs, including opioid analgesics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Analgesics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Acetaminophen
  • 6.3. Nonsteroidal Anti-Inflammatory Drugs
  • 6.4. Salicylates

7. Analgesics Market, by Type

  • 7.1. Introduction
  • 7.2. Non-Opioids
  • 7.3. Opioids

8. Analgesics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Rectal
  • 8.5. Topical
  • 8.6. Transdermal

9. Analgesics Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Analgesics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Analgesics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Analgesics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Assertio Therapeutics, Inc.
  • 3. Bausch Health Companies Inc.
  • 4. Baxter International Inc.
  • 5. Bayer AG
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. Endo Pharmaceuticals Inc.
  • 10. Glaxosmithkline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Purdue Pharmaceuticals L.P.
  • 15. Reckitt Benckiser Group PLC
  • 16. Sun Pharmaceutical Industries, Inc.
  • 17. Teva Pharmaceutical Industries Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦